Business · 11/01/2024Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Amryt Pharmaceuticals for Rare Pediatric Disease Product FILSUVEZ
Summary
The FDA is issuing a priority review voucher to Amryt Pharmaceuticals for its rare pediatric disease product FILSUVEZ, which meets the criteria set by the Federal Food, Drug, and Cosmetic Act.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →